Time to get serious about HIV antiretroviral resistance
Authors:
- Evan WoodEWEvan Wood
- Julio Sg MontanerJMJulio Sg Montaner
- 1 October 2011
- journal article
- editorial
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 11 (10) , 723-724
Abstract
No abstract availableFunding Information
- The US National Institutes of Health ((NIH R01 DA021525 and Avante Guarde Award 1DP1DA026182-01))
This publication has 14 references indexed in Scilit:
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational studyThe Lancet Infectious Diseases, 2011
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Thirty Years of HIV and AIDS: Future Challenges and OpportunitiesAnnals of Internal Medicine, 2011
- Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort studyThe Lancet Infectious Diseases, 2011
- Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment FailureJAMA, 2011
- Antiretroviral Therapies in Women after Single-Dose Nevirapine ExposureNew England Journal of Medicine, 2010
- Antiretroviral therapy and management of HIV infectionThe Lancet, 2010
- Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance DetectionClinical Infectious Diseases, 2010
- HIV prevention before HAART in sub-Saharan AfricaThe Lancet, 2002
- Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitableThe Lancet, 1999